EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation

Juan Ge, Yongfei Chen, Zongru Jiang, Shuang Qi, Jie Hu, Beilei Wang, Aoli Wang, Qingsong Liu, Hong Wu, Wenchao Wang, Jing Liu

Cellular Oncology · 29.04.2026 · 49 (3)

DOI: 10.1007/s13402-026-01215-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 29.04.2026. Verfasst von Juan Ge und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, P. R. China. Hauptthemen laut MEDLINE: Phosphoglycerate Kinase, Glycolysis, Autophagy, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Major Science and Technology Project of Anhui Province, the Key Research and Development Program of Anhui Province, the Youth Innovation Promotion Association of CAS support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoglycerate KinaseGlycolysisAutophagyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsProteolysisHumansErbB ReceptorsCell Line, TumorCell ProliferationAnimalsSignal TransductionMice, NudeXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AutophagyEGFR-positive ESCCPRAS40Phosphoglycerate kinase 1

Substanzen

Phosphoglycerate KinaseErbB ReceptorsPGK1 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, P. R. China.
  • University of Science and Technology of China, Hefei, Anhui, 230026, P. R. China.
  • Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, P. R. China.
  • Precision Cancer Medicine Engineering Research Center of Anhui Province, Hefei, Anhui, 230088, P. R. China.
  • Primary Cell Engineering Joint Laboratory of Anhui Province, Hefei, Anhui, 230088, P. R. China.
  • Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, P. R. China. wuhong@hmfl.ac.cn.

Förderung

  • the Major Science and Technology Project of Anhui Province
  • the Key Research and Development Program of Anhui Province
  • the Youth Innovation Promotion Association of CAS support
  • he National Natural Science Foundation of China
  • the CASHIPS Director's Fund
  • the CASHIPS Director’s Fund

Zitieren

APA

Ge, J., Chen, Y., Jiang, Z., Qi, S., Hu, J., Wang, B., Wang, A., Liu, Q., Wu, H., Wang, W., & Liu, J. (2026). Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation. Cellular Oncology, 49(3). https://doi.org/10.1007/s13402-026-01215-4

Vancouver

Ge J, Chen Y, Jiang Z, Qi S, Hu J, Wang B, et al. Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation. Cellular Oncology. 2026;49(3). doi:10.1007/s13402-026-01215-4

BibTeX
@article{Ge2026,
  author = {Ge, Juan and Chen, Yongfei and Jiang, Zongru and Qi, Shuang and Hu, Jie and Wang, Beilei and Wang, Aoli and Liu, Qingsong and Wu, Hong and Wang, Wenchao and Liu, Jing},
  title = {Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation},
  journal = {Cellular Oncology},
  year = {2026},
  volume = {49},
  number = {3},
  doi = {10.1007/s13402-026-01215-4}
}
Kostenlos starten →